Healthcare provider profile · identity verified

Sigrid A Ramirez, MD

General Practice · SANTURCE, PR · NPI 1184619702

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Gabapentin	Gabapentin	296	81
Losartan Potassium	Losartan Potassium	291	89
Amlodipine Besylate	Amlodipine Besylate	240	78
Famotidine	Famotidine	234	60
Atorvastatin Calcium	Atorvastatin Calcium	208	76
Omeprazole	Omeprazole	205	50
Synthroid	Levothyroxine Sodium	185	61
Simvastatin	Simvastatin	175	59
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	169	44
Pantoprazole Sodium	Pantoprazole Sodium	137	39
Temazepam	Temazepam	120	31
Alendronate Sodium	Alendronate Sodium	106	32
Rosuvastatin Calcium	Rosuvastatin Calcium	105	44
Alprazolam	Alprazolam	102	19
Metformin Hcl	Metformin Hcl	100	38
Tizanidine Hcl	Tizanidine Hcl	92	48
Clonazepam	Clonazepam	83	18
Levothyroxine Sodium	Levothyroxine Sodium	83	29
Fenofibrate	Fenofibrate Nanocrystallized	81	29
Dicyclomine Hcl	Dicyclomine Hcl	80	26
Hydrochlorothiazide	Hydrochlorothiazide	80	27
Diclofenac Potassium	Diclofenac Potassium	79	37
Fluticasone Propionate	Fluticasone Propionate	76	32
Lisinopril	Lisinopril	73	23
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	73	20
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	73	12
Albuterol Sulfate Hfa	Albuterol Sulfate	72	19
Dexamethasone	Dexamethasone	71	43
Tramadol Hcl	Tramadol Hcl	71	20
Clopidogrel	Clopidogrel Bisulfate	70	23
Sertraline Hcl	Sertraline Hcl	64	24
Metoprolol Tartrate	Metoprolol Tartrate	63	22
Albuterol Sulfate	Albuterol Sulfate	62	45
Triamcinolone Acetonide	Triamcinolone Acetonide	59	36
Metoprolol Succinate	Metoprolol Succinate	58	20
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	56	13
Tamsulosin Hcl	Tamsulosin Hcl	56	15
Azithromycin	Azithromycin	54	37
Montelukast Sodium	Montelukast Sodium	53	18
Diclofenac Sodium	Diclofenac Sodium	50	19
Jentadueto	Linagliptin/Metformin Hcl	46	11
Zolpidem Tartrate	Zolpidem Tartrate	45	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	44	12
Meclizine Hcl	Meclizine Hcl	43	11
Glimepiride	Glimepiride	42	14
Valsartan	Valsartan	39	15
Ezetimibe	Ezetimibe	37	16
Nabumetone	Nabumetone	37	13
Glipizide	Glipizide	36	12
Meloxicam	Meloxicam	36	17
Furosemide	Furosemide	32	14
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	31	suppressed
Pentoxifylline	Pentoxifylline	31	14
Naproxen	Naproxen	30	suppressed
Synjardy	Empagliflozin/Metformin Hcl	29	suppressed
Carvedilol	Carvedilol	28	11
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	28	suppressed
Acyclovir	Acyclovir	27	suppressed
Clobetasol Propionate	Clobetasol Propionate	27	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	27	suppressed
Enalapril Maleate	Enalapril Maleate	26	suppressed
Atenolol	Atenolol	25	suppressed
Endocet	Oxycodone Hcl/Acetaminophen	25	suppressed
Mometasone Furoate	Mometasone Furoate	25	16
Pregabalin	Pregabalin	24	suppressed
Celecoxib	Celecoxib	23	15
Hydralazine Hcl	Hydralazine Hcl	23	suppressed
Jardiance	Empagliflozin	23	suppressed
Loperamide	Loperamide Hcl	23	suppressed
Eliquis	Apixaban	22	suppressed
Lansoprazole	Lansoprazole	22	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	21	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	20	suppressed
Sucralfate	Sucralfate	20	suppressed
Ibuprofen	Ibuprofen	19	suppressed
Lumigan	Bimatoprost	19	suppressed
Tobramycin-Dexamethasone	Tobramycin/Dexamethasone	19	13
Ibandronate Sodium	Ibandronate Sodium	18	suppressed
Irbesartan	Irbesartan	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	14
Candesartan Cilexetil	Candesartan Cilexetil	17	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	17	suppressed
Orphenadrine Citrate	Orphenadrine Citrate	17	11
Prednisone	Prednisone	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	16	suppressed
Latanoprost	Latanoprost	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Betamethasone Valerate	Betamethasone Valerate	15	suppressed
Duloxetine Hcl	Duloxetine Hcl	15	suppressed
Humulin N	Insulin Nph Human Isophane	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	15	13
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Methotrexate	Methotrexate Sodium	14	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	13	suppressed
Atacand	Candesartan Cilexetil	13	suppressed
Baclofen	Baclofen	13	suppressed
Cilostazol	Cilostazol	13	suppressed
Humalog	Insulin Lispro	13	suppressed
Insulin Glargine	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Levofloxacin	Levofloxacin	12	11
Carbamazepine	Carbamazepine	11	suppressed
Methylprednisolone	Methylprednisolone	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error